Companies: 10,795·Total market cap: $144.5T
GSK plc

GSK plc

GSKNYSEHealthcare● Active
$51.52
+$0.25(+0.49%)
Market Cap$103.6B
P/E Ratio—
52W High$61.7
52W Low$35.45
Cash on HandFinancialsRevenue

GSK plc (GSK) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

GSK · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$3.40B▼ -8.5% vs prior year
FY · as of Dec 31, 2025 · Reported in GBP
Cash & Cash Equiv. (CCE)
$3.39B
cashAndCashEquivalents
Short-Term Investments
$9.0M
shortTermInvestments
YoY Change vs Prior Year
-8.5%
vs prior fiscal year
Latest Quarter
$4.54B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in GBP

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$3.40BCash on Hand
Total Debt$17.69BTotal Debt
Net Cash / Net Debt−$14.29BNet Debt Position
Cash vs Debt Ratio
Cash 16%Debt 84%

GSK plc carries a net debt position of $14.29B. Total debt ($17.69B) exceeds cash on hand ($3.40B). GSK plc cash vs debt ratio: 16% cash / 84% debt.

Net Cash = Cash & ST Investments − Total Debt$3.40B − $17.69B = −$14.29B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
GSK annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$3.40B-8.5%
Dec 31, 2024$3.71B-43.8%
Dec 31, 2023$6.61B-16.1%
Dec 31, 2022$7.88B+34.2%
Dec 31, 2021$5.87B-32.6%
GSK cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
GSK plc
GSK plcYOU
GSK
$3.40B3.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

GSK plc (GSK) cash on hand as of December 31, 2025 is $3.40B, comprising $3.39B in cash and cash equivalents (CCE) plus $9.0M in short-term investments — reported as GSK plc cash and short-term investments on the balance sheet (10-K filing). Also referred to as GSK plc cash reserves or cash position.

GSK plc annual cash on hand history shows decreased -8.5% in 2025: decreased -8.5% in 2025. GSK plc cash reserves in 2025 reflect the company's capital allocation strategy.

GSK plc carries total debt of $17.69B against cash of $3.40B, resulting in a net debt position of -$14.29B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

GSK cash on hand · 5 questions

As of December 31, 2025, GSK plc (GSK) has $3.40B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $3.39B in cash and cash equivalents (CCE) plus $8,984,000 in short-term investments. Latest quarter (March 31, 2026): $4.54B. Data sourced from the annual 10-K filing via FMP.

GSK cash on handGSK cash reservesGSK cash 2025how much cash does GSK have

▸ Source: FMP /balance-sheet-statement · US GAAP · GSK plc · GSK plc SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025